ContractLetter Agreement • November 5th, 2015 • Arbutus Biopharma Corp • Pharmaceutical preparations
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
AMENDING AGREEMENTAmending Agreement • November 5th, 2015 • Arbutus Biopharma Corp • Pharmaceutical preparations • New York
THIS AMENDMENT (this “Amendment”) is executed as of November 2, 2015, by and among Arbutus Biopharma Corporation (fka Tekmira Pharmaceuticals Corporation) (the “Company”), a British Columbia corporation, Roivant Sciences Ltd., Patrick T. Higgins, Michael J. McElhaugh, Michael J. Sofia and Bryce A. Roberts (such parties other than the Company being collectively referred to as the “OnCore Holders”).
LICENSE AGREEMENT Dated December 30, 2014 By and Between Cytos Biotechnology Ltd and OnCore Biopharma, Inc.License Agreement • November 5th, 2015 • Arbutus Biopharma Corp • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is dated as of December 30, 2014 (the “Execution Date”) by and between Cytos Biotechnology Ltd, a Swiss company having a place of business at Wagistrasse 25, 8952 Schlieren, Switzerland (“Licensor”), and OnCore Biopharma, Inc., a Delaware corporation having a place of business at 3805 Old Easton Road, Doylestown, PA 18902, USA (“OnCore”). Licensor and OnCore may be referred to herein as a “Party” or, collectively, as “Parties”.
